European vs. Egyptian HCV-4 patients with elevated baseline HCV RNA, treated with PEG-IFN-α2a and Ribavirin: The role of rapid and early virologic response

Hepatitis Monthly

Volumn 10, Issue 3, 2010, Pages 193-198

  Dimitroulopoulos, Dimitrios ^a   Elefsiniotis, Ioannis ^b   Pavlidis, Christos ^c   Xinopoulos, Dimitrios ^a   Tsamakidis, Klisthenis ^a   Patsavela, Stamatina ^a   Kypreos, Dimitrios ^a   Ferderigou, Ageliki ^a   Korkolis, Dimitrios ^a   Koutsounas, Sotirios ^c   Saroglou, Georgios ^b   Paraskevas, Emmanouil ^a  

^a Agios Savvas Cancer Hospital   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c IKA   (Greece)

Author keywords

EVR; Genotype 4; HCV; RVR; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; MIRTAZAPINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; EGYPT; ETHNICITY; EUROPE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS 4; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE; LEUKOCYTE COUNT; LIVER; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; VIRUS LOAD;

EID: 77954872107     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther. 2005;10(1):1-11.
2. Sharma SD. Hepatitis C virus: molecular biology & current therapeutic options. Indian J Med Res. 2010;131:17-34.
3. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol. 2005;3(10 Suppl 2):S97-S101.
4. Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology. 2008;47(4):1371- 83.
5. Payan C, Roudot-Thoraval F, Marcellin P, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat. 2005;12(4):405-13.
6. Nicot F, Legrand-Abravanel F, Sandres-Saune K, et al. Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. J Gen Virol. 2005;86(Pt 1):107-14.
7. Katsoulidou A, Sypsa V, Tassopoulos NC, et al. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat. 2006;13(1):19-27.
8. Fernandez-Arcas N, Lopez-Siles J, Trapero S, et al. High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses. J Med Virol. 2006;78(11):1429-35.
9. Kamal SM, Graham CS, He Q, et al. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis. 2004;189(7):1140-50.
10. Kamal SM, Turner B, He Q, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology. 2006;43(4):771-9.
11. Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat. 2007;14(7):460-7.
12. Koshy A, Marcellin P, Martinot M, Madda JP. Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver. 2000;20(4):335-9.
13. Zylberberg H, Chaix ML, Brechot C. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med. 2000;132(10):845-6.
14. Kamal SM, Madwar MA, Peters T, Fawzy R, Rasenack J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol. 2000;32(1):172-4.
15. Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005;54(6):858-66.
16. Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa- 2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol. 2004;99(9):1733-7.
17. Alfaleh FZ, Hadad Q, Khuroo MS, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int. 2004;24(6):568-74.
18. El-Zayadi AR, Attia M, Barakat EM, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of Peginterferon- alpha2b/ribavirin or induction-dose interferonalpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol. 2005;100(11):2447-52.
19. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology. 2007;46(6):1732-40.
20. Derbala MF, Al Kaabi SR, El Dweik NZ, et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa- 2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol. 2006;12(35):5692-8.
21. Diago M, Hassanein T, Rodes J, Ackrill AM, Sedarati F. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med. 2004;140(1):72-3.
22. Trapero-Marugan M, Moreno-Monteagudo JA, Garcia- Buey L, et al. Clinical and pathological characteristics and response to combination therapy of genotype 4 chronic hepatitis C patients: experience from a spanish center. J Chemother. 2007;19(4):423-7.
23. Legrand-Abravanel F, Nicot F, Boulestin A, et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol. 2005;77(1):66-9.
24. Soriano V, Nunez M, Sanchez-Conde M, et al. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4. Antivir Ther. 2005;10(1):167-70.
25. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa- 2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135(2):451-8.
26. Elefsiniotis IS, Pavlidis C, Dimitroulopoulos D, et al. Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity. J Viral Hepat. 2009;16(10):738-42.
27. Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30(3):342-55.
28. Shaker O, Ahmed A, Doss W, Abdel-Hamid M. MxA expression as marker for assessing the therapeutic response in HCV genotype 4 Egyptian patients. J Viral Hepat. 2009.
29. Zekri AR, El-Din HM, Bahnassy AA, et al. Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4. Virol J. 2007;4:16.